The Biopharmaceutics Classification System: Subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC

European Journal of Pharmaceutical Sciences

Volumn 57, Issue 1, 2014, Pages 152-163

  Tsume, Yasuhiro ^a   Mudie, Deanna M ^a   Langguth, Peter ^b   Amidon, Greg E ^a   Amidon, Gordon L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

BCS Class II; GastroPlus ; In vivo predictive dissolution; Simulation; Sub classification

Indexed keywords

ACID; BASE; BUFFER; CARVEDILOL; DANAZOL; FENOFIBRATE; IBUPROFEN; KETOCONAZOLE; KETOPROFEN; SURFACTANT; DRUG;

ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; BIOPHARMACEUTICS CLASSIFICATION SYSTEM; DISSOLUTION; DRUG ABSORPTION; DRUG SOLUBILITY; ENVIRONMENTAL FACTOR; FIRST PASS EFFECT; GASTROINTESTINAL TRACT; HUMAN; IN VITRO IN VIVO CORRELATION; IN VITRO STUDY; IN VIVO PREDICTIVE DISSOLUTION; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; PERMEABILITY; PH; PHARMACEUTICS; PHYSICAL PARAMETERS; PRIORITY JOURNAL; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; CLASSIFICATION; COMPUTER SIMULATION; INTESTINE; INTESTINE ABSORPTION; METABOLISM; NOMENCLATURE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PROCEDURES; REPRODUCIBILITY; SOLUBILITY;

ADMINISTRATION, ORAL; ANIMALS; BIOPHARMACEUTICS; COMPUTER SIMULATION; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; INTESTINES; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; REPRODUCIBILITY OF RESULTS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; TERMINOLOGY AS TOPIC;

EID: 84899945997     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2014.01.009     Document Type: Article

References (107)

1. D.R. Abernethy, and D.J. Greenblatt Ibuprofen disposition in obese individuals Arthritis Rheum. 28 1985 1117 1121 (Pubitemid 16250646)
2. S. Agrawal, and R. Panchagnula Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms Biopharm. Drug Dispos. 26 2005 321 334 (Pubitemid 41684538)
3. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 1995 413 420
4. K.S. Amidon, P. Langguth, H. Lennernas, L. Yu, and G.L. Amidon Bioequivalence of oral products and the Biopharmaceutics Classification System: science, regulation, and public policy Clin. Pharmacol. Ther. 90 2011 467 470
5. M.U. Anby, H.D. Williams, M. McIntosh, H. Benameur, G.A. Edwards, C.W. Pouton, and C.J. Porter Lipid digestion as a trigger for supersaturation: evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems Mol. Pharm. 2012
6. A. Avdeef, K.J. Box, J.E. Comer, C. Hibbert, and K.Y. Tam PH-metric log P 10. Determination of liposomal membrane-water partition coefficients of ionizable drugs Pharm. Res. 15 1998 209 215 (Pubitemid 28144231)
7. J.G. Baxter, C. Brass, J.J. Schentag, and R.L. Slaughter Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs J. Pharm. Sci. 75 1986 443 447 (Pubitemid 16083637)
8. C. Becker, J.B. Dressman, H.E. Junginger, S. Kopp, K.K. Midha, V.P. Shah, S. Stavchansky, and D.M. Barends Biowaiver monographs for immediate release solid oral dosage forms: rifampicin J. Pharm. Sci. 98 2009 2252 2267
9. E. Beetge, J. du Plessis, D.G. Muller, C. Goosen, and F.J. van Rensburg The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption Int. J. Pharm. 193 2000 261 264 (Pubitemid 30001870)
10. S.N. Bhattachar, E.J. Perkins, J.S. Tan, and L.J. Burns Effect of gastric pH on the pharmacokinetics of a BCS Class II compound in dogs: utilization of an artificial stomach and duodenum dissolution model and GastroPlus, simulations to predict absorption J. Pharm. Sci. 100 2011 4756 4765
11. S.N. Bhattachar, D.S. Risley, P. Werawatganone, and A. Aburub Weak bases and formation of a less soluble lauryl sulfate salt/complex in sodium lauryl sulfate (SLS) containing media Int. J. Pharm. 412 2011 95 98
12. N.R. Budha, A. Frymoyer, G.S. Smelick, J.Y. Jin, M.R. Yago, M.J. Dresser, S.N. Holden, L.Z. Benet, and J.A. Ware Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin. Pharmacol. Ther. 92 2012 203 213
13. N.R. Budha, L.Z. Benet, and J.A. Ware Response to "Drug interactions produced by proton pump inhibitors: not simply a pH effect" Clin. Pharmacol. Ther. 93 2013 151
14. J.M. Butler, and J.B. Dressman The developability classification system: application of biopharmaceutics concepts to formulation development J. Pharm. Sci. 99 2010 4940 4954
15. S.R. Carino, D.C. Sperry, and M. Hawley Relative bioavailability estimation of carbamazepine crystal forms using an artificial stomach-duodenum model J. Pharm. Sci. 95 2006 116 125
16. S.R. Carino, D.C. Sperry, and M. Hawley Relative bioavailability of three different solid forms of PNU-141659 as determined with the artificial stomach-duodenum model J. Pharm. Sci. 99 2010 3923 3930
17. S. Carlert, A. Palsson, G. Hanisch, C. von Corswant, C. Nilsson, L. Lindfors, H. Lennernas, and B. Abrahamsson Predicting intestinal precipitation - a case example for a basic BCS Class II drug Pharm. Res. 27 2010 2119 2130
18. S. Carlert, P. Akesson, G. Jerndal, L. Lindfors, H. Lennernas, and B. Abrahamsson In vivo dog intestinal precipitation of mebendazole: a basic BCS Class II drug Mol. Pharm. 9 2012 2903 2911
19. CDER, U.S.D.o.H.a.H.S.F.a.D.A.C.f.E.a.R., 2000. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System, FDA Guidance for Industry.
20. CDER/FDA, 2000. U.S. Department of Health and Human Services Food and Drug Administration Center for Evaluation and Research (CDER). Guidances for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System.
21. J.A. Cordero, L. Alarcon, E. Escribano, R. Obach, and J. Domenech A comparative study of the transdermal penetration of a series of nonsteroidal antiinflammatory drugs J. Pharm. Sci. 86 1997 503 508 (Pubitemid 27154769)
22. A. Dahan, and G.L. Amidon Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting Am. J. Physiol. Gastroint. Liver Physiol. 297 2009 G371 G377
23. N.M. Davies Clinical pharmacokinetics of flurbiprofen and its enantiomers Clin. Pharmacokinet. 28 1995 100 114
24. N.M. Davies Clinical pharmacokinetics of ibuprofen. The first 30 years Clin. Pharmacokinet. 34 1998 101 154 (Pubitemid 28077672)
25. N.M. Davies, and K.E. Anderson Clinical pharmacokinetics of naproxen Clin. Pharmacokinet. 32 1997 268 293 (Pubitemid 27160611)
26. S.S. Davis, J.G. Hardy, and J.W. Fara Transit of pharmaceutical dosage forms through the small intestine Gut 27 1986 886 892 (Pubitemid 16044258)
27. P.A. Dickinson, W.W. Lee, P.W. Stott, A.I. Townsend, J.P. Smart, P. Ghahramani, T. Hammett, L. Billett, S. Behn, R.C. Gibb, and B. Abrahamsson Clinical relevance of dissolution testing in quality by design AAPS J. 10 2008 380 390
28. U. Domanska, A. Pobudkowska, A. Pelczarska, and P. Gierycz pKa and solubility of drugs in water, ethanol, and 1-octanol J. Phys. Chem. B 113 2009 8941 8947
29. J.B. Dressman, and H. Lennernäs Oral Drug Absorption: Prediction and Assessment 2000 Marcel Dekker New York
30. J.B. Dressman, and C. Reppas In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs Eur. J. Pharm. Sci.: Official J. Eur. Fed. Pharm. Sci. 11 Suppl. 2 2000 S73 S80
31. J.B. Dressman, J. Hempenstall, J. Reppas, and C. Reppas The BCS: where do we go from here? Pharm. Technol. 25 2001 68 76
32. F. Faassen, and H. Vromans Biowaivers for oral immediate-release products: implications of linear pharmacokinetics Clin. Pharmacokinet. 43 2004 1117 1126 (Pubitemid 40013179)
33. H.M. Fadda, T. Sousa, A.S. Carlsson, B. Abrahamsson, J.G. Williams, D. Kumar, and A.W. Basit Drug solubility in luminal fluids from different regions of the small and large intestine of humans Mol. Pharm. 7 2010 1527 1532
34. Y. Fei, E.S. Kostewicz, M.T. Sheu, and J.B. Dressman Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach Eur. J. Pharm. Biopharm.: Official J. Arbeitsgemein. Pharm. Verfahrenstech. e.V. 2013
35. D.I. Friedman, and G.L. Amidon Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril Pharm. Res. 6 1989 1043 1047 (Pubitemid 20094227)
36. G. Geisslinger, S. Menzel, K. Wissel, and K. Brune Pharmacokinetics of ketoprofen enantiomers after different doses of the racemate Br. J. Clin. Pharmacol. 40 1995 73 75
37. GlaxoSmithKline, 2009. COREG tablets prescribing information.
38. C.H. Gu, D. Rao, R.B. Gandhi, J. Hilden, and K. Raghavan Using a novel multicompartment dissolution system to predict the effect of gastric pH on the oral absorption of weak bases with poor intrinsic solubility J. Pharm. Sci. 94 2005 199 208 (Pubitemid 40116383)
39. N.T. Hoa, and R. Kinget Design and evaluation of two-phase partition-dissolution method and its use in evaluating artemisinin tablets J. Pharm. Sci. 85 1996 1060 1063 (Pubitemid 26338918)
40. G. Holtmann, D.G. Kelly, B. Sternby, and E.P. DiMagno Survival of human pancreatic enzymes during small bowel transit: effect of nutrients, bile acids, and enzymes Am. J. Physiol. 273 1997 G553 G558
41. W.D. Hooper, M.J. Eadie, and R.G. Dickinson Single oral dose pharmacokinetics and comparative bioavailability of danazol in humans Biopharm. Drug Dispos. 12 1991 577 582
42. Y.C. Huang, J.L. Colaizzi, R.H. Bierman, R. Woestenborghs, and J. Heykants Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers Antimicrob. Agents Chemother. 30 1986 206 210 (Pubitemid 16038748)
43. V.C. Ibekwe, H.M. Fadda, E.L. McConnell, M.K. Khela, D.F. Evans, and A.W. Basit Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems Pharm. Res. 25 2008 1828 1835
44. P.P. Ige, R.K. Baria, and S.G. Gattani Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability Colloids Surf., B: Biointerf. 108 2013 366 373
45. J. Jinno, N. Kamada, M. Miyake, K. Yamada, T. Mukai, M. Odomi, H. Toguchi, G.G. Liversidge, K. Higaki, and T. Kimura In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol J. Controlled Release 130 2008 29 37
46. A. Kambayashi, and J.B. Dressman An in vitro-in silico-in vivo approach to predicting the oral pharmacokinetic profile of salts of weak acids: case example dantrolene Eur. J. Pharm. Biopharm.: Official J. Arbeitsgemein. Pharm. Verfahrenstech. e.V. 84 2013 200 207
47. N.A. Kasim, M. Whitehouse, C. Ramachandran, M. Bermejo, H. Lennernas, A.S. Hussain, H.E. Junginger, S.A. Stavchansky, K.K. Midha, V.P. Shah, and G.L. Amidon Molecular properties of WHO essential drugs and provisional biopharmaceutical classification Mol. Pharm. 1 2004 85 96
48. M. Kataoka, Y. Masaoka, Y. Yamazaki, T. Sakane, H. Sezaki, and S. Yamashita In vitro system to evaluate oral absorption of poorly water-soluble drugs: simultaneous analysis on dissolution and permeation of drugs Pharm. Res. 20 2003 1674 1680 (Pubitemid 37268286)
49. M. Kataoka, Y. Masaoka, S. Sakuma, and S. Yamashita Effect of food intake on the oral absorption of poorly water-soluble drugs: in vitro assessment of drug dissolution and permeation assay system J. Pharm. Sci. 95 2006 2051 2061 (Pubitemid 44433034)
50. M. Kataoka, K. Sugano, C. da Costa Mathews, J.W. Wong, K.L. Jones, Y. Masaoka, S. Sakuma, and S. Yamashita Application of dissolution/permeation system for evaluation of formulation effect on oral absorption of poorly water-soluble drugs in drug development Pharm. Res. 29 2012 1485 1494
51. M. Kataoka, K. Yano, Y. Hamatsu, Y. Masaoka, S. Sakuma, and S. Yamashita Assessment of absorption potential of poorly water-soluble drugs by using the dissolution/permeation system Eur. J. Pharm. Biopharm.: Official J. Arbeitsgemein. Pharm. Verfahrenstech. e.V. 2013
52. L.C. Kaus, and J.T. Fell Effect of stress on the gastric emptying of capsules J. Clin. Hosp. Pharm. 9 1984 249 251 (Pubitemid 14068747)
53. G.M. Keating, and K.F. Croom Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus Drugs 67 2007 121 153 (Pubitemid 46105094)
54. I. Kim, X.Y. Chu, S. Kim, C.J. Provoda, K.D. Lee, and G.L. Amidon Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase J. Biol. Chem. 278 2003 25348 25356 (Pubitemid 36835284)
55. H. Kortejarvi, A. Urtti, and M. Yliperttula Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates Eur. J. Pharm. Sci.: Official J. Eur. Fed. Pharm. Sci. 30 2007 155 166 (Pubitemid 46157177)
56. E.S. Kostewicz, U. Brauns, R. Becker, and J.B. Dressman Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media Pharm. Res. 19 2002 345 349 (Pubitemid 34211853)
57. E.S. Kostewicz, M. Wunderlich, U. Brauns, R. Becker, T. Bock, and J.B. Dressman Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine J. Pharm. Pharmacol. 56 2004 43 51 (Pubitemid 38195327)
58. I. Kovacevic, J. Parojcic, I. Homsek, M. Tubic-Grozdanis, and P. Langguth Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation Mol. Pharm. 6 2009 40 47
59. L. Lai, Z. Xu, J. Zhou, K.D. Lee, and G.L. Amidon Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase J. Biol. Chem. 283 2008 9318 9327
60. B.D. Laird, D. Peak, and S.D. Siciliano The effect of residence time and fluid volume to soil mass (LS) ratio on in vitro arsenic bioaccessibility from poorly crystalline scorodite J. Environ. Sci. Health A: Tox. Hazard Subst. Environ. Eng. 45 2010 732 739
61. V.N. Le, P. Leterme, A. Gayot, and M.P. Flament Influence of granulation and compaction on the particle size of ibuprofen-development of a size analysis method Int. J. Pharm. 321 2006 72 77 (Pubitemid 44247416)
62. C. Lin, J. Lim, C. DiGiore, R. Gural, and S. Symchowicz Comparative bioavailability of a microsize and ultramicrosize griseofulvin formulation in man J. Int. Med. Res. 10 1982 274 277 (Pubitemid 12092070)
63. K.K. Lindfors, J.M. Boone, T.R. Nelson, K. Yang, A.L. Kwan, and D.F. Miller Dedicated breast CT: initial clinical experience Radiology 246 2008 725 733
64. T. Loftsson, S.B. Vogensen, C. Desbos, and P. Jansook Carvedilol: solubilization and cyclodextrin complexation: a technical note AAPS PharmSciTech 9 2008 425 430
65. J.L. Madsen, and O.W. Krogsgaard Gastrointestinal scintiscanning: dosimetry Eur. J. Nucl. Med. 15 1989 260 261 (Pubitemid 19139375)
66. P.T. Mannisto, R. Mantyla, S. Nykanen, U. Lamminsivu, and P. Ottoila Impairing effect of food on ketoconazole absorption Antimicrob. Agents Chemother. 21 1982 730 733 (Pubitemid 12006519)
67. L. Marciani, E.F. Cox, C.L. Hoad, S. Pritchard, J.J. Totman, S. Foley, A. Mistry, S. Evans, P.A. Gowland, and R.C. Spiller Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome Gastroenterology 138 2010 469 477 477 e461
68. J.M. Miller, A. Beig, B.J. Krieg, R.A. Carr, T.B. Borchardt, G.E. Amidon, G.L. Amidon, and A. Dahan The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation Mol. Pharm. 8 2011 1848 1856
69. S. Moya, G.B. Sukhorukov, M. Auch, E. Donath, and H. Mohwald Microencapsulation of organic solvents in polyelectrolyte multilayer micrometer-sized shells J. Colloid Interface Sci. 216 1999 297 302 (Pubitemid 29385672)
70. D.M. Mudie, G.L. Amidon, and G.E. Amidon Physiological parameters for oral delivery and in vitro testing Mol. Pharm. 7 2010 1388 1405
71. D.M. Mudie, Y. Shi, H. Ping, P. Gao, G.L. Amidon, and G.E. Amidon Mechanistic analysis of solute transport in an in vitro physiological two-phase dissolution apparatus Biopharm. Drug Dispos. 33 2012 378 402
72. D.G. Muller, V. Stella, and A.P. Lotter Factors influencing the precipitation time of phenytoin in the presence of DDMS, one of its prodrugs Int. J. Pharm. 75 1991 201 209
73. S. Mutalik, P. Anju, K. Manoj, and A.N. Usha Enhancement of dissolution rate and bioavailability of aceclofenac: a chitosan-based solvent change approach Int. J. Pharm. 350 2008 279 290
74. R.L. Oberle, and G.L. Amidon The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon J. Pharmacokinet. Biopharm. 15 1987 529 544
75. R.L. Oberle, T.S. Chen, C. Lloyd, J.L. Barnett, C. Owyang, J. Meyer, and G.L. Amidon The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids Gastroenterology 99 1990 1275 1282 (Pubitemid 20381860)
76. J. Oliary, M. Tod, P. Nicolas, O. Petitjean, and G. Caille Pharmacokinetics of ibuprofen enantiomers after single and repeated doses in man Biopharm. Drug Dispos. 13 1992 337 344
77. R. Panchagnula, and S. Agrawal Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin Int. J. Pharm. 271 2004 1 4 (Pubitemid 38210078)
78. K. Peeters, R. De Maesschalck, H. Bohets, K. Vanhoutte, and L. Nagels In situ dissolution testing using potentiometric sensors Eur. J. Pharm. Sci.: Official J. Eur. Fed. Pharm. Sci. 34 2008 243 249
79. M. Perez de la Cruz Moreno, M. Moreno, M. Oth, S. Deferme, F. Lammert, J. Tack, J. Dressman, and P. Augustijns Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum J. Pharm. Pharmacol. 58 2006 1079 1089 (Pubitemid 44213641)
80. O. Planinsek, B. Kovacic, and F. Vrecer Carvedilol dissolution improvement by preparation of solid dispersions with porous silica Int. J. Pharm. 406 2011 41 48
81. H.N. Prajapati, D.M. Dalrymple, and A.T. Serajuddin A comparative evaluation of mono-, di- and triglyceride of medium chain fatty acids by lipid/surfactant/water phase diagram, solubility determination and dispersion testing for application in pharmaceutical dosage form development Pharm. Res. 29 2012 285 305
82. S.M. Reddy, V.R. Sinha, and D.S. Reddy Novel oral colon-specific drug delivery systems for pharmacotherapy of peptide and nonpeptide drugs Drugs Today (Barc.) 35 1999 537 580 (Pubitemid 29422129)
83. E. Rinaki, A. Dokoumetzidis, G. Valsami, and P. Macheras Identification of biowaivers among Class II drugs: theoretical justification and practical examples Pharm. Res. 21 2004 1567 1572 (Pubitemid 41184386)
84. C. Schiller, C.P. Frohlich, T. Giessmann, W. Siegmund, H. Monnikes, N. Hosten, and W. Weitschies Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging Aliment. Pharmacol. Ther. 22 2005 971 979 (Pubitemid 41634879)
85. J.J. Sheng, P.J. Sirois, J.B. Dressman, and G.L. Amidon Particle diffusional layer thickness in a USP dissolution apparatus II: a combined function of particle size and paddle speed J. Pharm. Sci. 97 2008 4815 4829
86. J.J. Sheng, D.P. McNamara, and G.L. Amidon Toward an in vivo dissolution methodology: a comparison of phosphate and bicarbonate buffers Mol. Pharm. 6 2009 29 39
87. P.J. Sinko, and G.L. Amidon Characterization of the oral absorption of beta-lactam antibiotics. II. Competitive absorption and peptide carrier specificity J. Pharm. Sci. 78 1989 723 727 (Pubitemid 20101917)
88. K. Sugano Aqueous boundary layers related to oral absorption of a drug: from dissolution of a drug to carrier mediated transport and intestinal wall metabolism Mol. Pharm. 7 2010 1362 1373
89. T. Takagi, C. Ramachandran, M. Bermejo, S. Yamashita, L.X. Yu, and G.L. Amidon A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan Mol. Pharm. 3 2006 631 643 (Pubitemid 46087480)
90. R. Takano, K. Furumoto, K. Shiraki, N. Takata, Y. Hayashi, Y. Aso, and S. Yamashita Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation Pharm. Res. 25 2008 2334 2344
91. R. Takano, M. Kataoka, and S. Yamashita Integrating drug permeability with dissolution profile to develop IVIVC Biopharm. Drug Dispos. 33 2012 354 365
92. Y. Tsume, and G.L. Amidon The biowaiver extension for BCS Class III drugs: the effect of dissolution rate on the bioequivalence of BCS Class III immediate-release drugs predicted by computer simulation Mol. Pharm. 7 2010 1235 1243
93. M. Tubic-Grozdanis, M.B. Bolger, and P. Langguth Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds AAPS J. 10 2008 213 226
94. M. Vertzoni, N. Fotaki, E. Kostewicz, E. Stippler, C. Leuner, E. Nicolaides, J. Dressman, and C. Reppas Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects J. Pharm. Pharmacol. 56 2004 453 462 (Pubitemid 38455610)
95. M. Vertzoni, J. Dressman, J. Butler, J. Hempenstall, and C. Reppas Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds Eur. J. Pharm. Biopharm.: Official J. Arbeitsgemein. Pharm. Verfahrenstech. e.V. 60 2005 413 417 (Pubitemid 40922839)
96. M. Vertzoni, A. Diakidou, M. Chatzilias, E. Soderlind, B. Abrahamsson, J.B. Dressman, and C. Reppas Biorelevant media to simulate fluids in the ascending colon of humans and their usefulness in predicting intracolonic drug solubility Pharm. Res. 27 2010 2187 2196
97. Y. Wang, B. Abrahamsson, L. Lindfors, and J.G. Brasseur Comparison and analysis of theoretical models for diffusion-controlled dissolution Mol. Pharm. 9 2012 1052 1066
98. H.D. Williams, M.U. Anby, P. Sassene, K. Kleberg, J.C. Bakala-N'Goma, M. Calderone, V. Jannin, A. Igonin, A. Partheil, D. Marchaud, E. Jule, J. Vertommen, M. Maio, R. Blundell, H. Benameur, F. Carriere, A. Mullertz, C.W. Pouton, and C.J. Porter Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion Mol. Pharm. 9 2012 3286 3300
99. H.D. Williams, P. Sassene, K. Kleberg, J.C. Bakala-N'Goma, M. Calderone, V. Jannin, A. Igonin, A. Partheil, D. Marchaud, E. Jule, J. Vertommen, M. Maio, R. Blundell, H. Benameur, F. Carriere, A. Mullertz, C.J. Porter, and C.W. Pouton Toward the establishment of standardized in vitro tests for lipid-based formulations, Part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations J. Pharm. Sci. 101 2012 3360 3380
100. H.D. Williams, N.L. Trevaskis, S.A. Charman, R.M. Shanker, W.N. Charman, C.W. Pouton, and C.J. Porter Strategies to address low drug solubility in discovery and development Pharmacol. Rev. 65 2013 315 499
101. S. Willmann, K. Thelen, C. Becker, J.B. Dressman, and J. Lippert Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs Eur. J. Pharm. Biopharm.: Official J. Arbeitsgemein. Pharm. Verfahrenstech. e.V. 76 2010 83 94
102. W.I. Wilson, Y. Peng, and L.L. Augsburger Comparison of statistical analysis and Bayesian Networks in the evaluation of dissolution performance of BCS Class II model drugs J. Pharm. Sci. 94 2005 2764 2776 (Pubitemid 43265398)
103. C.Y. Wu, and L.Z. Benet Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system Pharm. Res. 22 2005 11 23 (Pubitemid 40558141)
104. S. Yamashita, Y. Tanaka, Y. Endoh, Y. Taki, T. Sakane, T. Nadai, and H. Sezaki Analysis of drug permeation across Caco-2 monolayer: implication for predicting in vivo drug absorption Pharm. Res. 14 1997 486 491 (Pubitemid 27205009)
105. M. Yazdanian, K. Briggs, C. Jankovsky, and A. Hawi The "high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs Pharm. Res. 21 2004 293 299 (Pubitemid 38221975)
106. L.X. Yu Pharmaceutical quality by design: product and process development, understanding, and control Pharm. Res. 25 2008 781 791
107. H.Y. Yun, E. Joo Lee, S. Youn Chung, S.O. Choi, H. Kee Kim, J.T. Kwon, W. Kang, and K.I. Kwon The effects of food on the bioavailability of fenofibrate administered orally in healthy volunteers via sustained-release capsule Clin. Pharmacokinet. 45 2006 425 432